Wednesday, March 25, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

IHME COVID-19 Results Briefing

Daily reported cases in the last week increased to 68,900 per day on average compared
to 66,700 the week before, an increase of 3%

Daily deaths in the last week decreased slightly to 670 per day on average compared to
700 the week before. COVID-19 remains the number 2 cause of death in the
US this week.

The daily death rate is greater than 4 per million in Michigan.

We estimated that 30% of people in the US have been infected as of April 19.
Our estimate of the percent infected to date has increased considerably from last week
due to introducing corrections for waning antibodies in our analysis of seroprevalence
surveys.

Effective R, computed using cases, hospitalizations, and deaths, is greater than 1 in 34
states.

The infection-detection rate in the US is close to 40%. After correcting for
waning antibodies in seroprevalence surveys, our estimate of the infection-detection
rate is down from our previous estimates.

Based on GISAID and CDC sequence data combined with our variant spread model,
we estimate current prevalence of key variants. B.1.1.7 is becoming the
dominant variant in most of the US. While B.1.351 and P1 have been sequenced in
many states, as in Europe, these variants are not increasing in prevalence in the
presence of B.1.1.7.

Source: IHME

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!